<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817166</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-N/2012/ET-01</org_study_id>
    <secondary_id>2012-005821-59</secondary_id>
    <nct_id>NCT01817166</nct_id>
  </id_info>
  <brief_title>Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome</brief_title>
  <acronym>D-Lay-MS</acronym>
  <official_title>Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy and tolerance of 2 years of
      treatment with cholecalciferol (vitamin D3) in patients with a clinically isolated syndrome
      at high risk for MS (CIS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:

      A. evaluate clinical efficacy: delay to conversion; number of relapses/episodes per year B.
      evaluate efficacy in terms of resonance imaging parameters (cerebral/spinal MRI) C. evaluate
      efficacy in terms of slowing the progression of disability as measured by EDSS score and
      subscores D. measure and assess cognitive abilities (PASAT) E. evaluate changes in quality of
      life (EQ5D questionnaires, SF36, and TLS-TLS-QoL10 COPING10), fatigue questionnaire (FSMC)
      and anxiety / depression questionnaire (HADS) F. evaluate treatment tolerance G. to correlate
      changes in clinical and imaging parameters with the evolution of serum levels of 25(OH)D2 and
      25(OH)D3 H. establish a biobank of DNA and RNA from all patients in the study and conduct
      analyses of gene polymorphisms involved in the metabolism of vitamin D and the HLA system
      based on the increased levels of vitamin D after supplementation I. establish a biobank of
      CSF, plasma, blood cells, serum and RNA samples for patients in selected centers for research
      on prognostic biomarkers of conversion J. establish a biobank consisting of plasma tubes
      collected for the determination of 25-hydroxy-vitamin D K. Estimate the rate of discordance
      between the conversion decision made by the study neurologist and the result of the MRI
      re-interpretation performed at the end of the study as well as the proportion of patients
      identified a posteriori as as erroneously included according to the centralized reading.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 16, 2013</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion to MS yes/no</measure>
    <time_frame>24 months</time_frame>
    <description>Conversion to MS according to criteria described by McDonald (Polman et al 2005)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of relapse episodes (number per year)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new T1 lesions taking on Gadolinium highlighting</measure>
    <time_frame>3 months</time_frame>
    <description>qualitative variable: 0, 1, or &gt;1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new T1 lesions taking on Gadolinium highlighting</measure>
    <time_frame>12 months</time_frame>
    <description>qualitative variable: 0, 1, or &gt;1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new T1 lesions taking on Gadolinium highlighting</measure>
    <time_frame>24 months</time_frame>
    <description>qualitative variable: 0, 1, or &gt;1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyposignal T1 lesions (black holes)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyposignal T1 lesions (black holes)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyposignal T1 lesions (black holes)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesional burden in mm^3 for each cerebral MRI</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesional burden in mm^3 for each cerebral MRI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesional burden in mm^3 for each cerebral MRI</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of Gadolinium highlighted lesions on T1 images</measure>
    <time_frame>3 months</time_frame>
    <description>Exact number (semiautomatic measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of Gadolinium highlighted lesions on T1 images</measure>
    <time_frame>12 months</time_frame>
    <description>Exact number (semiautomatic measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of Gadolinium highlighted lesions on T1 images</measure>
    <time_frame>24 months</time_frame>
    <description>Exact number (semiautomatic measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized cerebral volume (SIENAX) obtained from a T13D sequence</measure>
    <time_frame>3 months</time_frame>
    <description>mm^3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized cerebral volume (SIENAX) obtained from a T13D sequence</measure>
    <time_frame>12 months</time_frame>
    <description>mm^3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized cerebral volume (SIENAX) obtained from a T13D sequence</measure>
    <time_frame>24 months</time_frame>
    <description>mm^3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global cerebral volume (mm^3)</measure>
    <time_frame>baseline versus 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS score, including all subscores</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS score, including all subscores</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS score, including all subscores</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS score, including all subscores</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS score, including all subscores</measure>
    <time_frame>after second MS episode (1st relapse)(maximum 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score for the PASAT 3 seconds section of the MSFC score</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score for the PASAT 3 seconds section of the MSFC score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score for the PASAT 3 seconds section of the MSFC score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score for the PASAT 3 seconds section of the MSFC score</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score for the PASAT 3 seconds section of the MSFC score</measure>
    <time_frame>after second MS episode (1st relapse)(maximum 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D questionnaire</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D questionnaire</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSMC fatigue scale</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSMC fatigue scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSMC fatigue scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSMC fatigue scale</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-QOL10 questionnaire</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-QOL10 questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-QOL10 questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-QOL10 questionnaire</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-Coping10 questionnaire</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-Coping10 questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-Coping10 questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLS-Coping10 questionnaire</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS questionnaire</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS questionnaire</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of adverse events</measure>
    <time_frame>baseline</time_frame>
    <description>Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2+D3 serum level (nmol/l)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2+D3 serum level (nmol/l)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2+D3 serum level (nmol/l)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2+D3 serum level (nmol/l)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2+D3 serum level (nmol/l)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2+D3 serum level (nmol/l)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2+D3 serum level (nmol/l)</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciuria/creatinuria</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciuria/creatinuria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciuria/creatinuria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciuria/creatinuria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciuria/creatinuria</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciuria/creatinuria</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciuria/creatinuria</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay until conversion to MS</measure>
    <time_frame>24 months</time_frame>
    <description>The number of days that pass from the beginning of treatment to conversion to MS according to McDonald 2005 criteria (Polman et al 2005)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>DNA sample (blood sample) for biobank</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemogram</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemogram</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemogram</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemogram</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemogram</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemogram</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemogram</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alanine amino transferase serum levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alanine amino transferase serum levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alanine amino transferase serum levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alanine amino transferase serum levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alanine amino transferase serum levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alanine amino transferase serum levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alanine amino transferase serum levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>aspartate aminotransferase serum levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>aspartate aminotransferase serum levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>aspartate aminotransferase serum levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>aspartate aminotransferase serum levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>aspartate aminotransferase serum levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>aspartate aminotransferase serum levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>aspartate aminotransferase serum levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alkaline phosphatase serum levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alkaline phosphatase serum levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alkaline phosphatase serum levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alkaline phosphatase serum levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alkaline phosphatase serum levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alkaline phosphatase serum levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>alkaline phosphatase serum levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum calcium levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum calcium levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum calcium levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum calcium levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum calcium levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum calcium levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum calcium levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum albumin levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum albumin levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum albumin levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum albumin levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum albumin levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum albumin levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum albumin levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum bilirubin levels</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum bilirubin levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum bilirubin levels</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum bilirubin levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum bilirubin levels</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum bilirubin levels</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum bilirubin levels</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum electrolyte panel</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum electrolyte panel</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum electrolyte panel</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum electrolyte panel</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum electrolyte panel</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum electrolyte panel</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum electrolyte panel</measure>
    <time_frame>upon conversion to MS (maximum 24 months)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Intervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vit D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Intervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.</description>
    <arm_group_label>Vit D</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging</intervention_name>
    <description>All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vit D</arm_group_label>
    <other_name>Cerebro-medullar MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lumbar puncture</intervention_name>
    <description>A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vit D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vit D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urine samples</intervention_name>
    <description>Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vit D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given his/her informed and signed consent

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is available for 24 months of follow-up

          -  The patient has had a classic CIS with the past 90 days

          -  Reference cerebro-medullary MRI scheduled within the 90 days after the beginning of
             symptoms

          -  With MRI (cerebro ± medullary) showing demyelination according to spatial spread
             criteria by Swanton (2006):

          -  At least 1 lesion in at least 2 of the 4 following territories: (1) Peri-ventricular;
             (2) Juxta-cortical; (3) Sub-tentorial; (4) Medullary

          -  No other suspected pathology

          -  Vitamin D level in blood less than 100 nmol / l at the pre-inclusion visit

          -  Women of childbearing potential must use very effective contraception for the duration
             of the study. A very effective contraceptive method is defined as a method resulting
             in a low failure rate (that is to say less than 1% per year) when used consistently
             and correctly, such as implants, injectables, combined oral contraceptives, IUDs,
             sexual abstinence, or partner with a vasectomy.

        Randomisation stratification criteria:

          -  The patient can also also meet the temporal dissemination criteria defined according
             to McDonald criteria 2010 (Polman et al., 2011), because this condition is currently
             not sufficient for prescribing a background treatment: Simultaneous presence of at
             least one asymptomatic lesion taking on contrast and at least one asymptomatic lesion
             not taking on contrast after injection of gadolinium

        Exclusion Criteria:

          -  The patient is participating in another study (this criteria does not apply to the
             POLAR study (RCB 2011-A01269-32); patients included in this study may simultaneously
             participate in the POLAR study)

          -  The patient is in an exclusion period determined by a previous study

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient refuses to sign the consent

          -  It is impossible to correctly inform the patient

          -  The patient is pregnant, parturient, or breastfeeding

          -  Major medical or psychiatric illness that, according to the investigator, would result
             in the patient running an unnecessary risk or that could affect compliance with the
             study protocol

          -  Vitamin D insufficiency linked to currently active digestive or more general diseases
             (celiac disease, inflammatory bowel disease, intestinal bypass, short bowel syndrome,
             cirrhosis, nephrotic syndrome, hyperthyroidism, rickets, hypoparathyroidism, cancer,
             granulomatous diseases and lymphomas)

          -  Moderate or severe renal insufficiency (creatinine clearance less than 60 ml / min)

          -  Epilepsy not adequately controlled by treatment

          -  Any illness requiring chronic treatment with corticosteroids

          -  Patient with osteoporosis or history of osteopenia

          -  Pathology requiring calcium intakes greater than 1 gram per day

          -  Current or past history of hypercalcemia

          -  Medications that affect the metabolism of vitamin D other than corticosteroids; e.g.
             anticonvulsants [phenobarbital, primidone, phenytoin] rifampicin, isoniazid,
             ketoconazole, 5-FU and leucovorin, thiazide diuretics.

          -  Situations accompanied by increased vulnerability to hypercalcemia, e.g. arrhythmia or
             known heart disease, treatment with digitalis, and subjects with nephrolithiasis.

          -  Contraindications to vitamin D3 as mentioned in the documentation for UVEDOSE

          -  Known hypersensitivity to gadolinium and / or known inability to undergo an MRI
             (pacemaker, osteosynthesis material, intraocular metal splinter, etc ....).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>56 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Thouvennot, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Thouvenot, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Thouvenot, MD, PhD</last_name>
    <phone>+33.(0)4.66.68.32.61</phone>
    <email>eric.thouvenot@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey M Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens - Hôpital Nord</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier Godefroy, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdullatif Al Khedr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Hôpital Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Confavreux, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Vukusic, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen Cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Defer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Derache Belpalme, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand - Hôpital Gabriel-Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Clavelou, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Thaite, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivania Patry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des Cèdres - Capio</name>
      <address>
        <city>Cornebarrieu</city>
        <zip>31700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claude Mekies, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thibault Moreau, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique - Hôpital Pierre Zobda-Quitman</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philippe Cabre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital A Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Casez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Vermersch, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Zephyr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Outteryck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Magy, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis Montcuquet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier de l'Institut Catholique de Lille</name>
      <address>
        <city>Lomme Cedex</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Hautecoeur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile Donzé-Parret, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Camu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand Carlander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahmoud Charif, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Labauge, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Debouverie, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Pittion-Vouyovitch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandrine Wiertlewski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Laplaud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Lebrun-Fresnay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Thouvenot, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Castelnovo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint-Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bruno Stankoff, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Giannesini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MAILLART Elisabeth - La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MAILLART Elisabeth, PH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Gout, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mickaël Bonnan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Perpignan - Hôpital Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Gaillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anais Dutray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Cornouaille - Site Quimper - Hôpital Laennec</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Coustans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ayman Tourbah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital PontChaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Edan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Le Page, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Deburghgraeve, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier Hannequin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand Bourre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Poissy - Saint-Germain-en-Laye</name>
      <address>
        <city>Saint-Germain-en-Laye</city>
        <zip>78100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Heinzlef, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saumur</name>
      <address>
        <city>Saumur Cedex</city>
        <zip>49403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Devy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérôme De Sèze, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Brassat, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Corcia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie Guennoc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Versailles - Hôpital Mignot</name>
      <address>
        <city>Versailles</city>
        <zip>78000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fernando Pico, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Nifle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Vichy - Jacques Larin</name>
      <address>
        <city>Vichy</city>
        <zip>03207</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Renato Colamarino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholecalciferol</keyword>
  <keyword>vitamin D</keyword>
  <keyword>immune disease</keyword>
  <keyword>clinically isolated syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

